STRIVE Phase III study shows Aimovig provides benefits in migraine

Novartis announced that new additional data from the STRIVE Phase III clinical study demonstrates Aimovig (erenumab) 70 mg and 140 mg significantly reduced monthly migraine days (MMD) and migraine-specific medication days (MSMD) for episodic migraine patients who have previously struggled to find effective and tolerable preventive therapies specifically designed for migraine prevention. STRIVE data show that 55% of patients on Aimovig 140 mg experienced at least a 50% reduction in the number of monthly migraine days requiring acute medication at week 52. Data demonstrated sustained efficacy of Aimovig through week 52 in episodic migraine patients who failed prior preventive treatments; reinforcing Novartis' commitment to reimagine medicine for patients across the spectrum of migraine.

These findings add to the breadth of clinical data which show the sustained efficacy of Aimovig across the spectrum of migraine, including in those who have failed prior preventive treatments. Data from the active treatment phase (ATP) of the STRIVE Phase III clinical study will be presented at the European Academy of Neurology annual meeting in Oslo, Norway.

Comment: Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks. Aimovig is the only CGRP inhibitor that does not need a loading dose or intravenous administration.